Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Stomach Neoplasms 30Carcinoma, Hepatocellular 22Small Cell Lung Carcinoma 15Colorectal Neoplasms 14Carcinoma, Non-Small-Cell Lung 14Sarcoma 13Ovarian Neoplasms 12Breast Neoplasms 12Triple Negative Breast Neoplasms 9Nasopharyngeal Carcinoma 9Esophageal Squamous Cell Carcinoma 9Cholangiocarcinoma 9Biliary Tract Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Osteosarcoma 6Lung Neoplasms 6Pancreatic Neoplasms 5Head and Neck Neoplasms 5Esophageal Neoplasms 5Uterine Cervical Neoplasms 4Thyroid Neoplasms 4Neoplasms 4Melanoma 4Solid Tumor 3Recurrence 3Neoplasm Metastasis 3Liver Neoplasms 3Glioma 3Gastric Adenocarcinoma 3Carcinoma, Adenoid Cystic 3

Interventions

fluzoparib 1enzalutamide 1apatinib 1Prednisone 1Pluvicto 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Metastatic Castration Resistant Prostate Cancer × apatinib × Clear all
NCT04869488 2025-01-24

A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
93 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡